查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586049

癌症恶病质市场：治疗方法、特征和分销管道划分 - 全球预测 2025-2030

Cancer Cachexia Market by Therapy (Combination Therapies, Corticosteroids, Progestogens), Functionality (Appetite Stimulators, Weight Loss Stabilizers), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症恶病质市场价值为20.9亿美元，预计到2024年将达到22.4亿美元，复合年增长率为7.53%，到2030年将达到34.8亿美元。

癌症恶病质是一种复杂的综合征，其特征是严重体重减轻、肌肉无力和食物摄取减少，常见于癌症患者。这种病症的定义超越了简单的厌食症，还包括导致重大发病和死亡风险的代谢变化。作为市场研究分析师，了解这种综合征的需要是开发有效的治疗方案，以改善受影响患者的生活品质和存活率。典型应用包括药物、营养食品和支持性护理，最终用途包括医院、癌症治疗中心和家庭护理机构。癌症发生率的增加推动了市场的成长，需要更个人化和全面的治疗解决方案。对安宁疗护和以患者为中心的治疗的日益关注正在进一步推动市场扩张。

主要市场统计
基准年[2023] 20.9亿美元
预测年份 [2024] 22.4亿美元
预测年份 [2030] 34.8亿美元
复合年增长率（%） 7.53%

影响成长的因素包括生物技术的进步和正在进行的代谢途径研究，为创新药物开发提供了机会。此外，老年人口的增加，更容易罹患癌症和恶病质，也增加了市场潜力。然而，复杂的药物开发流程、高成本和严格的监管要求等挑战构成了巨大的障碍。此外，癌症恶病质的异质性受到不同癌症类型和阶段的影响，使治疗通讯协定的标准化变得复杂。

有机会探索结合药物和非药物介入的多模态治疗方法。一个新兴的研究领域正在阐明导致恶病质的分子机制，这可能会导致标靶治疗。对个人化医疗和生物标记的关注可以带来满足个别患者需求的创新产品。製药公司、研究机构和医疗保健提供者之间的合作可以促进这些发展。

在癌症研究和治疗技术不断进步的推动下，市场具有高度动态性。专注于开发综合治疗方法、改善患者营养和加强整体患者管理系统的公司将拥有竞争优势。确定老年肿瘤学的利基市场并加强对患者恶病质管理的教育可以进一步推动成长。

市场动态：快速发展的癌症恶病质市场揭示的关键市场洞察

供需的动态交互作用正在改变癌症恶病质市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人口恶病质盛行率增加
    • 是否有适当的报销政策
    • 改善医疗基础设施并提高对癌症恶病质治疗的认识
  • 市场限制因素
    • 治疗费用上涨
  • 市场机会
    • 癌症恶病质治疗技术的进展
    • 增加研发活动以发现治疗方法
  • 市场挑战
    • 执行严格的监管要求和更长的 FDA 批准

波特的五力：驾驭癌症恶病质市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解癌症恶病质市场的外部影响

外部宏观环境因素在塑造癌症恶病质市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症恶病质市场的竞争格局

对癌症恶病质市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症恶病质市场供应商的绩效评估

FPNV 定位矩阵是评估癌症恶病质市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製癌症恶病质市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对癌症恶病质市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人恶病质盛行率增加
      • 是否有适当的报销政策
      • 改善医疗基础设施并提高治疗癌症恶病质的意识
    • 抑制因素
      • 治疗费用高
    • 机会
      • 治疗癌症恶病质的技术进展
      • 增加旨在发现治疗药物的研发活动
    • 任务
      • 执行严格的监管要求和长期 FDA核准
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症恶病质市场治疗

  • 联合治疗
  • 皮质类固醇
  • 黄体素

第七章依功能分類的癌症恶病质市场

  • 食慾兴奋剂
  • 减重稳定剂

第八章癌症恶病质市场：依通路

  • 医院商店
  • 网路药房
  • 零售药房

第九章美洲癌症恶病质市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太癌症恶病质市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲癌症恶病质市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AAVogen Inc.
  • Actimed Therapeutics Ltd.
  • Aeterna Zentaris Inc.
  • Aphios Corporation
  • Artelo Biosciences Inc.
  • AVEO Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Fresenius Kabi AG
  • Green Cross Wellbeing Corporation
  • Helsinn Healthcare SA
  • INOVIO Pharmaceuticals Inc.
  • Mankind Pharma Ltd.
  • Merck & Co. Inc.
  • MetaFines Co., Ltd.
  • NeuBase Therapeutics, Inc.
  • NGM Biopharmaceuticals Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Tetra Bio-Pharma
Product Code: MRR-02026C4C92B4

The Cancer Cachexia Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.24 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 3.48 billion by 2030.

Cancer cachexia is a complex syndrome characterized by severe weight loss, muscle wasting, and reduced food intake, frequently observed in cancer patients. The condition's definition extends beyond mere anorexia, encompassing metabolic changes that lead to significant morbidity and mortality risks. As a market research analyst, the necessity for understanding this syndrome lies in developing effective treatment options to improve the quality of life and survival rates of affected patients. Key applications include pharmaceuticals, nutritional supplements, and supportive care therapies, with end-use spanning hospitals, cancer treatment centers, and home care settings. Market growth is driven by increasing cancer prevalence, demanding more personalized and comprehensive therapeutic solutions. The growing focus on palliative care and patient-centric treatment further propels the market's expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.24 billion
Forecast Year [2030] USD 3.48 billion
CAGR (%) 7.53%

Factors impacting growth include advancements in biotechnology and ongoing research into metabolic pathways, providing opportunities for innovative drug development. The growing geriatric population, susceptible to cancer and, hence, cachexia, also boosts market potential. However, challenges such as complex drug development processes, high costs, and stringent regulatory requirements pose significant barriers. Furthermore, the heterogeneity of cancer cachexia, influenced by various cancer types and stages, complicates the standardization of treatment protocols.

Opportunities exist in exploring multi-modal treatment approaches, combining pharmacological and non-pharmacological interventions. Emerging research areas include understanding molecular mechanisms driving cachexia, which could lead to targeted therapies. Emphasis on personalized medicine and biomarkers offers potential for innovative products that cater to individual patient needs. Collaborations between pharmaceutical companies, research institutions, and healthcare providers can expedite these developments.

The market's nature is highly dynamic, driven by continual advancements in cancer research and therapeutic technologies. Companies focusing on developing integrated treatment regimes, improving patient nutrition, and enhancing overall patient management systems stand to gain a competitive edge. Identifying niche markets within geriatric oncology and enhancing patient education about cachexia management can further stimulate growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Cachexia Market

The Cancer Cachexia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cachexia amongst the geriatric population
    • Presence of adequate reimbursement policies
    • Improving healthcare infrastructure and rise in awareness to treat cancer cachexia
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Technological advancements for the treatment of cancer cachexia
    • Rising number of research and development activities for the discovery of therapeutic drugs
  • Market Challenges
    • Implementation of stringent regulatory requirements and lengthy FDA approval

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Cachexia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Cachexia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Cachexia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Cachexia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Cachexia Market

A detailed market share analysis in the Cancer Cachexia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Cachexia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Cachexia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Cachexia Market

A strategic analysis of the Cancer Cachexia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Cachexia Market, highlighting leading vendors and their innovative profiles. These include AAVogen Inc., Actimed Therapeutics Ltd., Aeterna Zentaris Inc., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Fresenius Kabi AG, Green Cross Wellbeing Corporation, Helsinn Healthcare SA, INOVIO Pharmaceuticals Inc., Mankind Pharma Ltd., Merck & Co. Inc., MetaFines Co., Ltd., NeuBase Therapeutics, Inc., NGM Biopharmaceuticals Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., and Tetra Bio-Pharma.

Market Segmentation & Coverage

This research report categorizes the Cancer Cachexia Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy, market is studied across Combination Therapies, Corticosteroids, and Progestogens.
  • Based on Functionality, market is studied across Appetite Stimulators and Weight Loss Stabilizers.
  • Based on Distribution Channel, market is studied across Hospital Stores, Online Pharmacy, and Retail Pharmacy Stores.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cachexia amongst the geriatric population
      • 5.1.1.2. Presence of adequate reimbursement policies
      • 5.1.1.3. Improving healthcare infrastructure and rise in awareness to treat cancer cachexia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements for the treatment of cancer cachexia
      • 5.1.3.2. Rising number of research and development activities for the discovery of therapeutic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Implementation of stringent regulatory requirements and lengthy FDA approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Cachexia Market, by Therapy

  • 6.1. Introduction
  • 6.2. Combination Therapies
  • 6.3. Corticosteroids
  • 6.4. Progestogens

7. Cancer Cachexia Market, by Functionality

  • 7.1. Introduction
  • 7.2. Appetite Stimulators
  • 7.3. Weight Loss Stabilizers

8. Cancer Cachexia Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Stores
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy Stores

9. Americas Cancer Cachexia Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Cachexia Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Cachexia Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AAVogen Inc.
  • 2. Actimed Therapeutics Ltd.
  • 3. Aeterna Zentaris Inc.
  • 4. Aphios Corporation
  • 5. Artelo Biosciences Inc.
  • 6. AVEO Pharmaceuticals Inc.
  • 7. Boehringer Ingelheim International GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. Fresenius Kabi AG
  • 10. Green Cross Wellbeing Corporation
  • 11. Helsinn Healthcare SA
  • 12. INOVIO Pharmaceuticals Inc.
  • 13. Mankind Pharma Ltd.
  • 14. Merck & Co. Inc.
  • 15. MetaFines Co., Ltd.
  • 16. NeuBase Therapeutics, Inc.
  • 17. NGM Biopharmaceuticals Inc.
  • 18. Ono Pharmaceutical Co., Ltd.
  • 19. Pfizer Inc.
  • 20. Tetra Bio-Pharma

LIST OF FIGURES

  • FIGURE 1. CANCER CACHEXIA MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER CACHEXIA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER CACHEXIA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER CACHEXIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER CACHEXIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER CACHEXIA MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PROGESTOGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER CACHEXIA MARKET SIZE, BY WEIGHT LOSS STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACY STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER CACHEXIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM CANCER CACHEXIA MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CANCER CACHEXIA MARKET SIZE, BY FUNCTIONALITY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. CANCER CACHEXIA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. CANCER CACHEXIA MARKET, FPNV POSITIONING MATRIX, 2023